Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2017.1304395
Abstract: Abstract Objectives: This study investigated the cost per responder and number needed to treat (NNT) in type 2 diabetes mellitus (T2DM) patients for lixisenatide compared to insulin intensification regimens using composite endpoints in the UK,… read more here.
Keywords: per responder; top glargine; cost per; responder ... See more keywords